Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03667014 · ClinicalTrials.gov registry record · Phase 4
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT03667014 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 34 participants.
The verdict
NCT03667014, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.
Interventions
- DRUG Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03667014
The ClinicalTrials.gov registry entry for NCT03667014 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab is the first listed.
NCT03667014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03667014 about?
NCT03667014 is a clinical study titled "The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients". This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.
What is the current status of trial NCT03667014?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2018-11-01. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT03667014?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03667014?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.